Company Overview

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on the development and commercialization of alpha-radiation cancer therapies. The company operates in the oncology and radiation therapy sectors and is best known for its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform, which is designed to deliver localized alpha radiation directly into solid tumors. The company’s technology is intended to treat a range of cancers while minimizing damage to surrounding healthy tissue. Its primary revenue and value drivers currently stem from clinical development activities, regulatory advancement, research collaborations, and future commercialization potential tied to the Alpha DaRT platform.

The company was founded based on research originating from Tel Aviv University and technology developed by Professor Yona Keisari and Professor Itzhak Kelson. Alpha Tau Medical later evolved into a publicly traded company listed on Nasdaq under the ticker DRTS following a business combination transaction completed in 2022. The company has positioned itself within the emerging targeted radiotherapy market, emphasizing localized treatment approaches for solid tumors that may be difficult to treat through conventional surgery, chemotherapy, or external beam radiation.

Business Operations

Alpha Tau Medical conducts operations primarily through the development, testing, and regulatory advancement of its Alpha DaRT technology platform. The company’s activities include clinical trials, manufacturing development, intellectual property management, physician training, and regulatory engagement across multiple jurisdictions. Revenue generation remains limited and primarily associated with research and development collaborations and early-stage commercialization activities, as the company continues progressing through clinical and regulatory pathways rather than operating at large-scale commercial maturity.

The company maintains operations and collaborations in both Israel and the United States, while also supporting clinical activities in additional international markets. Alpha Tau Medical controls proprietary radiation delivery technology and related patents associated with alpha-emitting radionuclide applications in oncology. The company has worked with hospitals, academic medical centers, and clinical research institutions to expand trials involving skin, pancreatic, breast, head and neck, and other tumor indications. Public disclosures also indicate collaboration with regulatory and medical institutions to support multicenter studies and future commercialization infrastructure.

Strategic Position & Investments

Alpha Tau Medical’s strategic direction centers on expanding the clinical validation and regulatory approvals of the Alpha DaRT platform across multiple cancer indications and geographic markets. The company has emphasized growth through clinical trial expansion, physician adoption initiatives, manufacturing scale-up capabilities, and continued investment in intellectual property. Its strategy reflects broader industry interest in targeted radiopharmaceuticals and precision oncology therapies, particularly treatments designed to improve localized tumor control while reducing systemic toxicity.

The company has invested in broadening its research and development pipeline and pursuing regulatory engagement with agencies including the U.S. Food and Drug Administration. Alpha Tau Medical has also highlighted efforts to strengthen production and supply-chain capabilities for radioactive sources used in treatment delivery. While the company does not publicly report a large portfolio of independently operated subsidiaries compared with larger pharmaceutical groups, its value proposition is strongly linked to proprietary oncology technology development and strategic collaborations within academic and medical research ecosystems. Data regarding material acquisitions or large-scale portfolio holdings remains limited based on available public sources.

Geographic Footprint

Alpha Tau Medical is headquartered in Jerusalem, Israel, with operational and corporate activities extending into the United States and other international markets participating in clinical studies. The company’s presence is concentrated in regions with advanced oncology research infrastructure and supportive regulatory pathways for innovative medical technologies. Clinical collaborations and trial activity have involved institutions across North America, Europe, and parts of the Middle East.

The company’s international footprint is primarily driven by clinical development and regulatory expansion rather than broad commercial distribution at this stage. Alpha Tau Medical has sought to establish influence within global oncology and radiopharmaceutical markets through partnerships with hospitals, cancer centers, and academic institutions. Its cross-border operational model supports multicenter trials and future commercialization efforts targeting multiple healthcare systems internationally.

Leadership & Governance

Alpha Tau Medical was founded around scientific discoveries developed by researchers associated with Tel Aviv University, including Professor Yona Keisari and Professor Itzhak Kelson, whose work contributed to the underlying Alpha DaRT technology. The company’s leadership has emphasized advancing innovative oncology treatments through evidence-based clinical development, international regulatory engagement, and physician-centered adoption strategies.

Key executives and leadership figures include:

• Uzi Sofer – Chief Executive Officer
• Raphael Mechoulam – Scientific leadership contributor associated historically with research activities
• Prof. Yona Keisari – Co-inventor and scientific founder
• Prof. Itzhak Kelson – Co-inventor and scientific founder
• Sharon Malka – Chief Financial Officer

The company’s governance approach has focused on clinical execution, intellectual property development, and long-term expansion within the targeted radiotherapy sector. Public filings and corporate disclosures indicate continued emphasis on regulatory compliance, research oversight, and strategic clinical partnerships as core components of management philosophy.